title: Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
abstract: OBJECTIVE
  Analysis of multiple clinical and pathological factors in patients undergoing therapeutic hyperthermic isolated limb perfusion for extremity melanoma can identify variables with prognostic significance.
  
  
  METHODS
  Retrospective review of a prospectively collected limb perfusion database with a median follow-up interval of 32.2 months.
  
  
  METHODS
  Single-institution tertiary care surgical oncology unit.
  
  
  METHODS
  We report a series of 59 consecutive therapeutic hyperthermic isolated limb perfusion treatments (14 upper extremity and 45 lower extremity) in 54 patients with melanoma from January 1, 1995, through December 31, 2002, using a standard melphalan dosing protocol. At the time of perfusion, 31 cases had fewer than 10 lesions, with none greater than 3 cm in diameter. The remaining 28 cases had 10 or more lesions or at least 1 lesion greater than 3 cm in diameter.
  
  
  METHODS
  Response, recurrence, and survival were assessed in relation to multiple demographic, clinical, and technical variables using chi2, log-rank, and Kaplan-Meier survival analyses.
  
  
  RESULTS
  The 3-year survival for the entire cohort was 54%. Thirty-three (56%) of the 59 perfusion treatments resulted in a persistent complete response of at least 6 months' duration. Statistical analysis showed that patients with no evidence of regional nodal involvement had a significantly lower incidence of distant recurrence (P = .02). Those patients achieving a complete response to therapy had a survival advantage (P = .03).
  
  
  CONCLUSIONS
  In patients undergoing therapeutic hyperthermic isolated limb perfusion for in-transit melanoma, the ability to achieve a complete response following treatment, independent of regional nodal status, was the strongest predictor of long-term survival.
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Aloia
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Grubbs
authors.forename: Mark
authors.initials: M
authors.lastname: Onaitis
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Mosca
authors.forename: Tsung-Yen
authors.initials: TY
authors.lastname: Cheng
authors.forename: Hilliard
authors.initials: H
authors.lastname: Seigler
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Tyler
mesh_terms: D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D016009:Chi-Square Distribution; D005121:Extremities; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome